News
Sorrento Therapeutics rejects takeover offer.
Sorrento Therapeutics, Inc. announced that, after reviewing the latest acquisition proposal in consultation with its advisors, Sorrento’s Board of Directors (the “Board”) determined that the offer significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders. Sorrento’s management continues to execute on the core drug development and to pursue multiple potential strategic alliances and transactions. Accordingly, the Board unanimously rejected the acquisition proposal.
Type: industry